These new advances are exemplified by a new era of personalized therapy in the IMMUNOGAST phase II Trial (ClinicalTrials.gov #NCT04739202) for recurrent GC based on TCGA sub-type and trialling immunotherapy (anti-PD-L1, atezolizumab) plus ipatasertib (AKT inhibitor) for EBV+ GC, which exhibits amplified JAK2, ErbB2, PD-L1 and PD-L2 (Table 1). This evidence concerns the gene AKT1 and gastric cancer.